| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/14/2000 | CA2375912A1 Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| 12/14/2000 | CA2375882A1 Metalloprotease inhibitors |
| 12/14/2000 | CA2375874A1 Use of riluzole for the treatment of multiple sclerosis |
| 12/14/2000 | CA2375861A1 Method and markers for prognosticating efficacy of anticancer agents |
| 12/14/2000 | CA2375854A1 Novel liposomal vector complexes and their use in gene therapy |
| 12/14/2000 | CA2375843A1 Compositions and methods for inhibiting cell death |
| 12/14/2000 | CA2375734A1 Benzothiazinone and benzoxazinone compounds |
| 12/14/2000 | CA2375702A1 Nasal preparations |
| 12/14/2000 | CA2375371A1 Oil-core compositions for the sustained release of hydrophobic drugs |
| 12/14/2000 | CA2374851A1 Tek antagonists |
| 12/14/2000 | CA2374654A1 Thrombin inhibitors |
| 12/14/2000 | CA2374460A1 Inhibitors of metalloproteinases |
| 12/14/2000 | CA2374001A1 Alpha or beta emitters attached to fragments in radioimmunotherapy |
| 12/14/2000 | CA2373336A1 Peroxynitrite decomposition catalysts and methods of use thereof |
| 12/14/2000 | CA2373279A1 Dna methyltransferase inhibitors |
| 12/14/2000 | CA2371434A1 Compositions and methods for the treatment of tumor |
| 12/14/2000 | CA2371158A1 Diaminothiazoles and their use for inhibiting protein kinases |
| 12/14/2000 | CA2370013A1 Tricyclic fused heterocycle compounds, process for preparing the same and use thereof |
| 12/14/2000 | CA2339900A1 Composition for implementing a cytotoxic, in particular an antitumoral or antiviral, treatment in a mammal |
| 12/14/2000 | CA2293162A1 Acidic buffered nasal spray |
| 12/13/2000 | EP1059100A2 Combinations of CRF antagonists and renin-angiotensin system inhibitors |
| 12/13/2000 | EP1059095A1 Pump type metering device |
| 12/13/2000 | EP1059090A1 Remedies for brain infarction |
| 12/13/2000 | EP1059085A1 Langerhans cell migration inhibitors |
| 12/13/2000 | EP1059084A2 Rapidly absorbed liquid compositions containing an amine and a NSAID |
| 12/13/2000 | EP1059083A2 A solid pharmaceutical preparation for dialysis and a process for producing the same |
| 12/13/2000 | EP1059041A1 The combined use of triglycerides containing medium chain fatty acids and exogenous lipolytic enzymes as feed supplements |
| 12/13/2000 | EP1058726A2 Novel mechanically sensitive mammal potassium channel family activated by polyunsaturated fatty acids and their use particularly for screening medicines |
| 12/13/2000 | EP1058698A1 Preparation for prevention and healing of inflammation affections |
| 12/13/2000 | EP1058691A1 Caspase-8 interacting proteins |
| 12/13/2000 | EP1058690A1 Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes |
| 12/13/2000 | EP1058687A1 Nucleosides |
| 12/13/2000 | EP1058686A1 2'-fluoronucleosides |
| 12/13/2000 | EP1058684A1 Glycine transport inhibitors |
| 12/13/2000 | EP1058683A1 Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof |
| 12/13/2000 | EP1058682A1 Heterocyclic diarylmethylene derivatives, methods of preparing them and their uses in therapeutics |
| 12/13/2000 | EP1058681A1 Novel allylthiopyridazine derivatives and process for preparing the same |
| 12/13/2000 | EP1058680A1 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists |
| 12/13/2000 | EP1058679A1 Synthesis of epothilones, intermediates thereto and analogues therof |
| 12/13/2000 | EP1058561A1 Solubilizing delivery systems and method of manufacture |
| 12/13/2000 | EP1058560A1 Topical ophthalmic preparations containing immunosuppressive agents |
| 12/13/2000 | EP1058559A1 Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor |
| 12/13/2000 | EP1058553A2 Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy |
| 12/13/2000 | EP1058552A1 Steroid derived antibiotics |
| 12/13/2000 | EP1058551A1 Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders and autism |
| 12/13/2000 | EP1058550A1 Substituted semicarbazides and the use thereof |
| 12/13/2000 | EP1058549A1 THROMBIN OR FACTOR Xa INHIBITORS |
| 12/13/2000 | EP1058548A1 New use |
| 12/13/2000 | EP1058547A1 Pharmaceutical compositions containing the phospholipase inhibitor sodium 3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate |
| 12/13/2000 | EP1058546A1 Composition and method for treating macular disorders |
| 12/13/2000 | EP1058545A1 Cancer management with tamoxifen and gammalinolenic acid |
| 12/13/2000 | EP1058544A1 Inhibition of tnf activity |
| 12/13/2000 | EP1058542A1 Method for producing encased spherical granular grains |
| 12/13/2000 | EP1058541A1 Sustained-release preparation for aii antagonist, production and use thereof |
| 12/13/2000 | EP1058539A1 Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same |
| 12/13/2000 | EP1058500A1 The helios gene |
| 12/13/2000 | EP0954277B1 Cosmetic self-tanning agent having a sunscreen effect |
| 12/13/2000 | EP0927196A4 Polymers containing polysaccharides such as alginates or modified alginates |
| 12/13/2000 | EP0914144B1 Therapeutic uses of bpi protein products for human meningococcemia |
| 12/13/2000 | EP0914120A4 Anti-viral compounds |
| 12/13/2000 | EP0906097A4 Anti-viral compounds |
| 12/13/2000 | EP0900371A4 Systems and methods for quantifying photoreactions in light activated materials |
| 12/13/2000 | EP0858330B1 Compositions containing hydroperoxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| 12/13/2000 | EP0802784B1 Nutrient medium for use as a culture medium for epidermal cells, and uses thereof |
| 12/13/2000 | EP0749438B1 Novel silyl compounds and their use |
| 12/13/2000 | EP0725641B1 NOVEL INHIBITORS OF URIDINE PHOSPHORYLASE (UrdPase) AND DIHYDROURACIL DEHYDROGENASE (DHUDase) |
| 12/13/2000 | EP0724583B1 Pyridazino quinoline compounds |
| 12/13/2000 | CN1276797A Low-toxicity human interferon-alpha analog |
| 12/13/2000 | CN1276794A Triplex forming oligonucleotides and their use in anti-HBV |
| 12/13/2000 | CN1276793A Methylenebisphosphonic acid derivs. |
| 12/13/2000 | CN1276791A Macrolides with antitumor activity |
| 12/13/2000 | CN1276790A Carboxamidothiazole derivs., preparation, pharmaceutical composition contg. them |
| 12/13/2000 | CN1276789A 4-aminothiazole derivs, their preparation and their use as inhibitors of cyclin-dependent kinases |
| 12/13/2000 | CN1276786A 3-aryl-succinamido-hydroxamic acids, method for producing said acids and medicaments contg. same |
| 12/13/2000 | CN1276785A N-aroylphenylalanine derivs. |
| 12/13/2000 | CN1276784A Cyclic amino acids and derivs. thereof useful as pharmaceutical agents |
| 12/13/2000 | CN1276782A 2-aminotetralines, process for their preparation, and pharmaceutical compositions, for prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies |
| 12/13/2000 | CN1276724A Eprosartan arginyl charge-neutralization-complex and process for its production and formulation |
| 12/13/2000 | CN1276723A Dithiolopyrrolones and their corresponding monoxides and dioxides as antineoplastic agent |
| 12/13/2000 | CN1276722A N, N-bis(phenylcarbamoylmethyl) dimethylammonium chloride and derivs in treatment of pain |
| 12/13/2000 | CN1276721A Use of 6,7-substd. 2-aminotetralines suitable for preparing pharmaceutical composition for therapeutic treatment of inflammatory and/or autoimmune pathologies |
| 12/13/2000 | CN1276720A Formulations and method for reducing toxicity of antineoplastic agent |
| 12/13/2000 | CN1276719A Rapidly disintegrating methylcellulose tablets |
| 12/13/2000 | CN1276718A Rapidly disintegrating methylcellulose tablets |
| 12/13/2000 | CN1276715A Method and composition for causing skin lightening |
| 12/13/2000 | CN1276714A Use of 17-'alpha'-estradiol for treatment of aged or sundamaged skin and./or skin atrophy |
| 12/13/2000 | CN1276704A Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing abuse of alcohol in healthy subjects |
| 12/13/2000 | CN1276370A Process for preparing anticancer compound, and intermediate |
| 12/13/2000 | CN1276221A Anal fissure ointment and its preparing process |
| 12/13/2000 | CN1276213A Medicine for treating diseases in chicken respiratory tract |
| 12/13/2000 | CN1276212A Functional oligose food |
| 12/13/2000 | CN1276211A Use of non-peptides NK3-antagonist |
| 12/13/2000 | CN1276210A Application of carbonic anhydrase inhibitor in preparing male contraceptives |
| 12/13/2000 | CN1276209A Application of tripterygium plant extract in preventing and curing diseases in nervous system |
| 12/13/2000 | CN1276208A Formaldehyde injection for treating infective diseases of animal |
| 12/13/2000 | CN1276205A Turmeric as antiirritant in composition contg. hydroxy acid or retinene derivs. |
| 12/13/2000 | CN1059446C Pharmaceutical composition and compounds for contraception, and their use |
| 12/13/2000 | CN1059445C Erythromycin derivs, method for preparing same and use thereof as drugs |
| 12/13/2000 | CN1059444C Method for extracting crocin for preventing and treating angicardiopathy |
| 12/13/2000 | CN1059443C Tetracylic 1,4-oxazine compound, its preparing method and medicinal composition contg. same |